These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22854290)

  • 41. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genital fistulas in female Crohn's disease patients.: clinical characteristics and response to therapy.
    de la Poza G; López-Sanroman A; Taxonera C; Marín-Jimenez I; Gisbert JP; Bermejo F; Opio V; Muriel A
    J Crohns Colitis; 2012 Apr; 6(3):276-80. PubMed ID: 22405162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.
    Quin A; Kane S; Ulitsky O
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):278-81. PubMed ID: 18364718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
    Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
    Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dacryoadenitis, an extra-intestinal manifestation of Crohn's disease.
    Wong JC; Rossman D; Bressler B
    Am J Gastroenterol; 2010 Aug; 105(8):1904-6. PubMed ID: 20686473
    [No Abstract]   [Full Text] [Related]  

  • 47. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A; Pendyala P; Arora P; Sitrin MD
    J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bell's palsy in a patient receiving adalimumab for Crohn's disease.
    Lu LX; Marshall JK
    J Crohns Colitis; 2013 Apr; 7(3):e115. PubMed ID: 22868065
    [No Abstract]   [Full Text] [Related]  

  • 50. Cutaneous Crohn's disease presenting as genital warts: successful treatment with adalimumab.
    Lestre S; Ramos J; João A; Serrão V
    Eur J Dermatol; 2010; 20(4):504-5. PubMed ID: 20507839
    [No Abstract]   [Full Text] [Related]  

  • 51. Duodenal Crohn's disease successfully treated with adalimumab.
    Tursi A
    Endoscopy; 2011; 43 Suppl 2 UCTN():E22. PubMed ID: 21271523
    [No Abstract]   [Full Text] [Related]  

  • 52. EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after adalimumab treatment.
    Liu L; Charabaty A; Ozdemirli M
    J Crohns Colitis; 2013 Apr; 7(3):e118-9. PubMed ID: 22902264
    [No Abstract]   [Full Text] [Related]  

  • 53. Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect.
    Kotze PG; de Barcelos IF; da Silva Kotze LM
    J Crohns Colitis; 2013 Dec; 7(11):e599-600. PubMed ID: 23849401
    [No Abstract]   [Full Text] [Related]  

  • 54. Randomized controlled trials in maintenance of remission in Crohn's disease.
    D'Incà R; Caccaro R
    Rev Recent Clin Trials; 2012 Nov; 7(4):270-83. PubMed ID: 23092231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
    Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transient menorrhagia without adalimumab discontinuation in a patient with Crohn's disease.
    Katsanos KH; Tsianos VE; Tsianos EV
    J Crohns Colitis; 2010 Sep; 4(3):348. PubMed ID: 21122527
    [No Abstract]   [Full Text] [Related]  

  • 57. The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA.
    Erim DO; Mahendraratnam N; Okafor PN; Wheeler SB
    J Crohns Colitis; 2015 Aug; 9(8):669-75. PubMed ID: 25987351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease.
    Nguyen KD; Alexis R; Schwarz SM
    J Pediatr Gastroenterol Nutr; 2010 Feb; 50(2):225-6. PubMed ID: 19841594
    [No Abstract]   [Full Text] [Related]  

  • 59. Crohn's disease diagnosis during adalimumab treatment.
    Fernández Salazar L; Barrio Andrés J; González Hernández JM
    Scand J Gastroenterol; 2013 Feb; 48(2):254-5. PubMed ID: 23061423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.